Evidence map›Paper›PMID 39989614›Full record

ArticleOpen medicine (Warsaw, Poland)2025

Modulatory effects of

Qing Wang, Ting Zhang, Xinting Feng, Peng Chen, Ye Feng, Haoqiang Huang, Yinhua Qian, Yang Guo, Zifei Yin

Abstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qing WangDepartment of Orthopaedics, Kunshan Affiliated Hospital of Nanjing University of Chinese Medicine, Kunshan, Jiangsu, 215300, China.
Ting ZhangDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Xinting FengDepartment of Sports Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Peng ChenDepartment of Sports Medicine, Peking University Shenzhen Hospital, Shenzhen, 518000, China.
Ye FengSchool of Stomatology, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, China.
Haoqiang HuangDepartment of Orthopaedics, Kunshan Affiliated Hospital of Nanjing University of Chinese Medicine, Kunshan, Jiangsu, 215300, China.
Yinhua QianDepartment of Orthopaedics, Kunshan Affiliated Hospital of Nanjing University of Chinese Medicine, Kunshan, Jiangsu, 215300, China.
Yang GuoDepartment of Traumatology and Orthopedics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Zifei YinDepartment of Orthopaedics, Kunshan Affiliated Hospital of Nanjing University of Chinese Medicine, No. 388 Zu Chong Zhi Road, Kunshan, Jiangsu, 215300, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osteoporosis (OP) is a systemic bone disorder marked by reduced bone mass and disrupted microstructure, leading to higher fracture risk. Epidemiological data from China show a 20.7% prevalence in women and 14.4% in men over 50, underscoring a pressing health issue given the aging population. More drugs to inhibit OP progression should be explored, and their biological mechanisms confirmed in preclinical studies. Methods: In this study, we utilized Results: LBP significantly promotes osteoblast proliferation, migration, and osteogenic differentiation. Conversely, it inhibits the intrinsic apoptotic response in osteoblasts. For osteoclasts, LBP suppressed their proliferation, migration, and osteoclastic differentiation while enhancing their natural apoptosis. These results were confirmed by classical protein pathway detection experiments. Conclusion: LBP showcases potential therapeutic properties against OP, particularly in modulating osteoblast/osteoclast activities. While its exact mechanisms through vital signaling pathways remain to be fully elucidated, LBP's prominent effects suggest that it is a promising agent for OP intervention, warranting further in-depth studies.

Indexed as

apoptosisLycium barbarum polysaccharideosteoblast/osteoclast differentiationosteoporosisproliferationsignaling pathways

Identifiers

PMID39989614
PMCPMC11843162

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.